|
WO2021055538A1
|
|
Methods of use for kv7 channel activators
|
|
SG11202008030WA
|
|
Kv7 channel activators compositions and methods of use
|
|
US2020062714A1
|
|
BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS
|
|
AU2016210640A1
|
|
Compositions and methods of using (r)-pramipexole
|
|
EP3572405A1
|
|
Benzoimidazol-1,2-yl amides as kv7 channel activators
|
|
EP3033081A1
|
|
Compositions and methods for treating chronic urticaria
|
|
CA2921378A1
|
|
Compositions and methods for treating plasma cell disorders and b-cell prolymphocytic disorders
|
|
AU2014287067A1
|
|
Treating elevated levels of eosinophils and/or basophils
|
|
WO2014145852A2
|
|
Imidazo(4,5-b) pyridin-2-yl amides as kv7 channel activators
|
|
WO2014134569A1
|
|
Compositions and methods for treating amyotrophic lateral sclerosis in responders
|
|
EP2961404A1
|
|
Compositions and methods for treating amyotrophic lateral sclerosis in responders
|
|
US2014329869A1
|
|
Compositions and methods for treating amyotrophic lateral sclerosis in responders
|
|
US2015018397A1
|
|
Compositions and methods for treating conditions related to increased eosinophils
|
|
AU2013209376A1
|
|
Compositions and methods of using (r)-pramipexole
|
|
US2015126745A1
|
|
Synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
|
